Announcing: RiskScore Available for All Ancestries

The first and only genetic test to blend comprehensive assessment for hereditary cancer risk with the precision of genomic breast cancer risk assessment for patients of all ancestries

Your patients need a complete answer

Achieving better patient outcomes requires a new approach to cancer risk assessment

Only 5% of patients with a significant family history of breast cancer have an identifiable genetic syndrome1

100%

MyRisk with RiskScore provides a personalized genetic answer for up to 100% of eligible, unaffected patients, regardless of ancestry

Click here to receive a test kit

RiskScore: Leading the way in breast cancer risk prediction

Included in the Myriad MyRisk Hereditary Cancer test, RiskScore delivers a personalized 5-year and remaining lifetime risk for breast cancer.

Precision beyond Tyrer-Cuzick using genomic insights

RiskScore is the only breast cancer risk assessment test that incorporates the patient’s own clinical risk factors, family history, and unique genetic, ancestry-informed breast cancer risk markers.

MyRisk and RiskScore

Current eligibility for RiskScore

  • Women – between ages 18 and 84
  • No personal history of breast cancer, LCIS, hyperplasia, atypical hyperplasia, or a breast biopsy with unknown results
  • Negative for breast cancer related gene mutation*

Offer your patients comprehensive genetic insights

Watch this video to learn more about the journey to equity

Precision tests inform personalized patient care

56% of tested women need additional care

For women tested in a preventive setting1, more than half will have a cancer risk high enough to warrant a medical management plan above what is recommended for the general population. A fraction are due to a high-risk mutation, and the majority are due to the patient’s personalized risk assessment, including RiskScore.

Myriad MyRisk Management Tool

Included with both positive and negative results, the Myriad MyRisk Management Tool details relevant societal guidelines, personalized to your patient, based on their RiskScore and family history risk assessment. The easy-to-read format to provides you and your patient clarity and confidence as you form a plan together.

MyRisk Report Image

Contact a Myriad Representative

Scientific innovation to serve all patients

An endless pursuit of scientific innovation for all patients through the power of personalized genetic insights

Watch Recorded Webinar

Provide your information below to be redirected to watch the webinar.





Myriad needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, please review our Privacy Policy.

Hidden Fields










Overcoming barriers through scientific discovery

Barriers prevented polygenic risk scores for breast cancer from being available for women of all ancestries. In order to offer precision breast cancer risk assessment for women of all ancestries, Myriad took steps to address some of these challenges.

Scientific discovery timeline

Deliver the power of cutting-edge genetics in your office

Click here to receive a test kit

Ensure your patients have access to equitable insights

All patients deserve to know their risk

At Myriad Genetics, we believe that personalized genetic tests need to be accurate and accessible for people of all ancestries. Across our portfolio of products, we are committed to providing equity in care, investing in science that benefits patients of all ancestries, and the availability of precision genetic insights for all patients.

Our mission and purpose at Myriad Genetics

Our mission and purpose at Myriad Genetics is to advance health and wellbeing for all, empowering every individual by revealing the answers inside each of us. It is more relevant than ever, and we are committed to fulfilling it – working together to uncover new opportunities, make health more precise and personal, and push the frontiers of what’s possible.

Click here to receive a test kit

Partner with Myriad to offer MyRisk with RiskScore

References

  1. Myriad Internal Data Based on OBGYN & Primary Care Settings
  2. Kurian, et al. Performance of the IBIS/Tyrer-Cuzick model of breast cancer risk by race and ethnicity in the Women’s Health Initiative. Published in Cancer 2021.
  3. Hughes, et al. Development and Validation of a Combined Residual Risk Score to Predict Breast Cancer Risk in Unaffected Women Negative for Mutations on a Multi-Gene Hereditary Cancer Panel. Presented at SABCS 2017.
  4. Hughes, et al. Development and Validation of a Polygenic Score to Predict Breast Cancer Risk in Unaffected Hispanic Women Negative for Mutations on a Multi-Gene Hereditary Cancer Panel. Presented at SABCS 2018.
  5. Hughes, et al. A novel method for unbiased risk prediction and its application to the combined residual risk score incorporating SNPs and the Tyrer-Cuzick_v7 breast cancer model. Presented at Basser Symposium 2019.
  6. Kurian, et al. Performance of the IBIS/Tyrer-Cuzick Model by Race/Ethnicity in the Women’s Health Initiative. Presented at ASCO 2020.
  7. Hughes, et al. Development and Validation of a Clinical Polygenic Risk Score to Predict Breast Cancer Risk. Published in JCO Precision Oncology 2020.
  8. Hughes, et al. Integrating Clinical and Polygenic Factors to Predict Breast Cancer Risk in Women Undergoing Genetic Testing. Published in JCO Precision Oncology 2021.
  9. Hughes, et al. Ancestrally unbiased polygenic breast cancer (BC) risk assessment. Presented at ASCO 2021.

*Must also not have any blood relatives with a known high-risk breast cancer-related gene mutation. European or Ashkenazi Jewish patients with a CHEK2 mutation who meet other clinical eligibility criteria will receive a RiskScore.

Myriad's family of products

2022 Myriad, the Myriad logo, MyriadPro, the MyriadPro logo, Myriad MyRisk Hereditary Cancer, the Myriad MyRisk Hereditary Cancer logo, BRACAnalysis, the BRACAnalysis logo, Prolaris, the Prolaris logo, Foresight, the Foresight logo, GeneSight, the GeneSight logo, MyChoice, MyChoice logo, Endopredict, the Endopredict logo, Prequel, the Prequel logo are either trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and other jurisdictions.